Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis.
Inamo J, Keegan J, Griffith A, Ghosh T, Horisberger A, Howard K, Pulford JF, Murzin E, Hancock B, Dominguez ST, Gurra MG, Gurajala S, Jonsson AH, Seifert JA, Feser ML, Norris JM, Cao Y, Apruzzese W, Bridges SL, Bykerk VP, Goodman S, Donlin LT, Firestein GS, Bathon JM, Hughes LB, Filer A, Pitzalis C, Anolik JH, Moreland L, Hacohen N, Guthridge JM, James JA, Cuda CM, Perlman H, Brenner MB, Raychaudhuri S, Sparks JA; Accelerating Medicines Partnership RA/SLE Network; Holers VM, Deane KD, Lederer J, Rao DA, Zhang F.
Inamo J, et al. Among authors: bykerk vp.
J Clin Invest. 2025 Mar 17;135(6):e185217. doi: 10.1172/JCI185217.
J Clin Invest. 2025.
PMID: 40091833
Free PMC article.